Similarly, Eric Polley, PhD, a UChicago data science and public health expert, recently led a study published in Nature Cardiovascular Research that used statistical modeling to emulate a clinical trial comparing the effects of four different classes of diabetes medication in patients with moderate cardiovascular risk
Anaesth Rep 2024;12:e12278.ArticlePubMedPMC 18
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to Eli Lilly, adults in the Phase 3 trials all lost weight with orforglipron and on the highest dose of 36 mg of orforglipron, the trial participants lost about 27 pounds over the course of 72 weeks or about 12% of their body weight, which is meaningful but not quite as high as some injectables
For people with type 2 diabetes, insufficient medication doses can lead to poor blood sugar control, potentially causing long-term complications like nerve damage, kidney problems, or cardiovascular issues
